Email Updates

You are here

The ECHO Trial Results: Time to Act

June 27, 2019

<em>Px Pulse</em> Logo

In early June, Px Pulse posted an episode exploring the questions under investigation in the ECHO trial, a large study looking at three contraceptives to determine if any of them increased a woman’s risk of HIV.

Since then, leaders of the trial, formally called Evidence for Contraceptive options in HIV Outcomes, announced their findings: The study shows no substantial difference in HIV acquisition among women using three different, safe and effective contraceptive methods: DMPA-IM, the copper IUD or the LNG implant.

These data provide strong evidence to address the longstanding uncertainty around DMPA-IM and HIV, but they also sound an alarm-- HIV infection rates among the women in the study in East and Southern Africa were almost 4 percent, elevating the urgent need for improved HIV prevention efforts and integrated sexual and reproductive health services, all with women at the center.

In this episode, two veteran women’s advocates from Kenya and South Africa, Jaqueline Wambui and Yvette Raphael, talk about what these data mean for advocacy now. Helen Rees and Nelly Mugo, members of the leadership team of the ECHO study, explain the trial results and their implications. And the World Health Organization’s James Kiarie shares the importance of the WHO guidelines and more.

Listen to the full podcast (16:21)


Additional Resources

Study Results and Background
Public Statements